BeOne Medicines AG (ONC) Stock: Price, Forecast & Analyst Target
BeOne Medicines AG (ONC) — MoonshotScore 96/100 (Exceptional band), calculated Nov 18, 2026. Price $403.60 (-2.34%), as of the Nov 18, 2026 trading session; market cap $46.1B.
Educational signal · not a buy or sell recommendation · How to read this
BeOne Medicines AG · ONC · NASDAQ · Healthcare · Biotechnology
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · BeOne Medicines AG (ONC)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a strong balance sheet and elite growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $1.89B (Q3 FY2026, quarter ended Sep 2026)
- EPS beat 6 of the last 8 reports
- Altman Z 7.27 · Piotroski F 6
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 88 | Exceptional | |
| 88 | Exceptional | |
| 96 | Exceptional | |
| 96 | Exceptional | |
| 96 | Exceptional | |
| 96 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $403.60 | |
| Change on the day | -2.34% | |
| 52-week range | $253.95–$424.73 | |
| Market capitalisation | $46.1B | — |
| Price / earnings (trailing) | 65.11 | |
| Shares traded on the day | 243.1K | |
| Beta (volatility vs the S&P 500) | 0.52 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for BeOne Medicines AG (ONC): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is BeOne Medicines AG (ONC), and what does it report?
Short answer
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. BeOne Medicines AG (ONC) is listed on NASDAQ. BeOne Medicines AG (ONC) is classified as Healthcare / Biotechnology. SEC filing business address: C/O Beone Medicines I Gmbh, Aeschengraben 27, 21ST Floor, Basel, 4051. It employs 12,000 people and is led by John V. Oyler. In Q3 FY2026 it reported revenue of $1.89B and net income of $385M. The market values it at $46.1B.
What do the latest results show for BeOne Medicines AG (ONC)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $1.89B. Against analyst estimates the company has EPS beat 6 of the last 8 reports.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $1.89B | $385M | $3.28 (diluted) |
| Q2 FY2026 | $1.71B | $237M | $2.05 (diluted) |
| Q1 FY2026 | $1.51B | $227M | $1.96 (diluted) |
| Q4 FY2025 | $1.50B | $67M | $0.59 (diluted) |
What are the financial strengths and risks for BeOne Medicines AG (ONC)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway. The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 7.27 · Piotroski F 6. Trailing ratios: ROE 18.2% · ROA 9.3% · current ratio 3.55 · earnings yield 1.5% · free-cash-flow yield 3.4%.
What should you watch next at BeOne Medicines AG (ONC)?
Short answer · as of
Current published price targets run low $370.00 · high $470.00 · consensus $426.50 · median $422.50 against a quoted price of $403.60 (as of Nov 18, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does BeOne Medicines AG compare with its peers?
Short answer
BeOne Medicines AG's score ranks tied for 3rd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $68.29 Nov 18, 2026 | $16.7B | 98 5-pillar Nov 18, 2026 | |
| $577.34 Nov 18, 2026 | $24.6B | 97 5-pillar Nov 18, 2026 | |
| BeOne Medicines AG (ONC) — this page | $403.60 | $46.1B | 96 |
| $941.25 Nov 18, 2026 | $59.2B | 96 5-pillar Nov 18, 2026 | |
| $270.33 Nov 18, 2026 | $17.7B | 96 5-pillar Nov 18, 2026 | |
| $945.53 Nov 18, 2026 | $97.8B | 95 5-pillar Nov 18, 2026 | |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $117.80 Nov 18, 2026 | $24.0B | 91 5-pillar Nov 18, 2026 | |
| $177.33 Nov 18, 2026 | $50.0B | 83 5-pillar Nov 18, 2026 | |
| $75.23 Nov 18, 2026 | $36.1B | 80 5-pillar Nov 18, 2026 | |
| $385.78 Nov 18, 2026 | $46.3B | 79 5-pillar Nov 18, 2026 | |
| $68.67 Nov 18, 2026 | $39.5B | 73 5-pillar Nov 18, 2026 | |
| $50.97 Nov 18, 2026 | $31.4B | 72 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $370.00 – $470.00
- Consensus target
- $426.50
- Median target
- $422.50
Consensus record · Captured .
Measured against a quoted price of $403.60 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 9, 2026
- Transactions
- 240
- Identified insiders
- 15
- Purchases
- 0
- Sales
- 162
- Other transactions
- 78
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ONC in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ONC in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about BeOne Medicines AG (ONC)?
Common Questions About ONC (Healthcare)
These answers are editorial: 1 of these 9 answers is drawn from the ONC research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ONC?
ONC carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is ONC a good stock to buy?
Stock Expert AI does not rate ONC buy, sell or hold. BeOne Medicines AG carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ONC stock price today?
The last price recorded for BeOne Medicines AG (ONC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ONC price target?
The analyst consensus price target for BeOne Medicines AG (ONC), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the key growth opportunities for ONC in healthcare?
BeOne Medicines has several significant growth opportunities within the healthcare sector. A major driver is the potential for expanding the approved indications and geographic reach of its existing commercial assets, particularly Tevimbra and Brukinsa.
What are the key factors to evaluate for ONC?
BeOne Medicines AG (ONC) holds a MoonshotScore in the high range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Not financial advice.
How frequently does ONC data refresh on this page?
ONC's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ONC's recent stock price performance?
BeOne Medicines AG (ONC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ONC overvalued or undervalued right now?
The trailing P/E of BeOne Medicines AG (ONC) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 30 figures on this page — 1 from SEC filings and earnings calls, 24 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com